A bold approach to improving outcomes
At Urovant, we live our core values every day, working together to create meaningful change. We bring passion, purpose, and care to our efforts in urology, and these qualities continue to drive us forward. We are excited to explore new possibilities for the future.
Our product pipeline
Vibegron is being investigated in COURAGE, a phase 3, double-blind, randomized, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of vibegron in men with overactive bladder (OAB) symptoms on pharmacological therapy for benign prostatic hyperplasia (BPH).
URO-902 is being investigated in a phase 2a, randomized, double-blind, placebo-controlled, multicenter trial to evaluate the efficacy, safety, and tolerability of a single physician-administered dose of a novel gene therapy for patients with overactive bladder (OAB) who have not been adequately managed with oral or transdermal pharmacologic therapy for OAB.
Vibegron is being investigated in COURAGE, a phase 3, double-blind, randomized, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of vibegron in men with overactive bladder (OAB) symptoms on pharmacological therapy for benign prostatic hyperplasia (BPH).
URO-902 is being investigated in a phase 2a, randomized, double-blind, placebo-controlled, multicenter trial to evaluate the efficacy, safety, and tolerability of a single physician-administered dose of a novel gene therapy for patients with overactive bladder (OAB) who have not been adequately managed with oral or transdermal pharmacologic therapy for OAB.
Visit Clinicaltrials.gov to learn more about clinical trials in urology.
Learn more
Building for a brighter future
Urovant is seeking licensing opportunities as well as new innovations that can accelerate our mission to improve the quality of care for patients, their families, and care partners.
Urovant Medical Affairs
Urovant Sciences Medical Affairs supports our ongoing product development efforts, providing scientific support to healthcare professionals, including opportunities for investigator-initiated trials and medical education grants.